ArticleEuropean journal of medical research2025
Alterations in gut microbiome and fecal metabolome in functional dyspepsia patients: insights into pathophysiological mechanisms.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastrointestinal microbiota dysregulation is recognized as a key factor in the pathogenesis of functional dyspepsia (FD). Previous investigations have focused predominantly on the microbiota associated with the oral, gastric, and duodenal mucosa. However, the intestinal microbiome and fecal metabolome in FD patients remain poorly characterized. This study aims to evaluate their alterations, thereby providing novel insights into the pathophysiological mechanisms of FD.
methodsFecal samples from 30 FD patients and 19 healthy controls (HCs) were subjected to 16S rRNA sequencing and metabolomics to characterize microbial-metabolic profiles, followed by Spearman correlation analysis to explore the associations between differentially abundant taxa and metabolites.
resultsCompared with the HCs, the FD group presented greater microbial richness but comparable diversity, along with increased abundances of Akkermansia and Ruminococcus_gnavus_group and decreased levels of Dorea, Collinsella, and Agathobacter (p < 0.05). AUC analysis revealed Akkermansia as a potential biomarker for FD (AUC = 0.848, 95% CI: 0.708-0.988). Furthermore, the levels of the fecal metabolites phosphatidylglycerol (PG) and phosphatidylcholine (PC) were significantly reduced in the FD group (p < 0.05). KEGG enrichment analysis revealed that these metabolites were involved in glycerophospholipid metabolism. Spearman correlation analysis revealed negative associations between Ruminococcus_gnavus_group, Fusobacterium, Erysipelatoclostridium, and PG/PC (p < 0.05).
conclusionsThe FD group presented concurrent alterations in the gut microbiome and fecal metabolites. Specifically, gut microbiota-derived metabolites, such as PG and PC, may disrupt host glycerophospholipid metabolism, contributing to FD pathogenesis. Given that this is an exploratory study with a small sample size and cross-sectional design, these results require validation in larger, longitudinal cohorts and should be interpreted with caution.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.